Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
1.420
-0.020 (-1.39%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Galmed Pharmaceuticals Employees
As of December 31, 2023, Galmed Pharmaceuticals had 8 total employees, including 3 full-time and 5 part-time employees. The number of employees decreased by 2 or -20.00% compared to the previous year.
Employees
8
Change (1Y)
-2
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$790,500
Market Cap
2.14M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
GLMD News
- 12 days ago - Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PRNewsWire
- 6 months ago - Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PRNewsWire
- 6 months ago - Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PRNewsWire
- 1 year ago - Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis - PRNewsWire
- 1 year ago - Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study - PRNewsWire
- 1 year ago - Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire